Protalix BioTherapeutics, Inc.
AMEX:PLXBiotechnology
+$0.09 today
- Market cap
- $254.64M
- Beta
- 0.01
- P/E (TTM)
- 11.0
- EPS (TTM)
- $0.19
Volume 0.96M
Average 0.81M
Income Statement
Follow revenue through to earnings.
Revenue
$52.74M
FY 2025 · Annual
-1.2% YoYOperating Income
-$5.50M
FY 2025 · Annual
Net Income
-$6.60M
FY 2025 · Annual
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 38.35M | 47.64M | 65.49M | 53.4M | 52.74M |
| Cost of Revenue | 16.35M | 19.59M | 22.98M | 24.32M | 27.51M |
| Gross Profit | 22M | 28.05M | 42.51M | 29.08M | 25.24M |
| Gross Margin | 57.4% | 58.9% | 64.9% | 54.5% | 47.8% |
| Research & Development | 29.73M | 29.35M | 17.09M | 12.97M | 19.05M |
| Selling, General & Admin | 12.73M | 11.71M | 14.96M | 12.19M | 11.68M |
| Operating Expenses | 42.46M | 41.06M | 32.05M | 25.16M | 30.74M |
| Depreciation & Amortization | 1.12M | 1.09M | 1.19M | 1.3M | 1.47M |
| EBITDA | (18.94M) | (10.78M) | 12.94M | 6.52M | (2.95M) |
| EBITDA Margin | -49.4% | -22.6% | 19.8% | 12.2% | -5.6% |
| Operating Income | (20.46M) | (13.01M) | 10.46M | 3.92M | (5.5M) |
| Operating Margin | -53.4% | -27.3% | 16.0% | 7.3% | -10.4% |
| Interest Income | 401K | 1.15M | 1.29M | 1.3M | 1.08M |
| Interest Expense | 7.52M | 2.53M | 3.18M | 1.06M | 1.19M |
| Other Income / Expenses | (7.12M) | (1.38M) | (1.89M) | 237K | (108K) |
| Income Before Tax | (27.58M) | (14.4M) | 8.57M | 4.15M | (5.61M) |
| Pre-Tax Margin | -71.9% | -30.2% | 13.1% | 7.8% | -10.6% |
| Income Tax Expense | 0 | 530K | 254K | 1.22M | 996K |
| Net Income | (27.58M) | (14.93M) | 8.31M | 2.93M | (6.6M) |
| Net Margin | -71.9% | -31.3% | 12.7% | 5.5% | -12.5% |
| EPS (Basic) | (0.62) | (0.31) | 0.12 | 0.04 | (0.08) |
| EPS (Diluted) | (0.62) | (0.31) | 0.10 | 0.04 | (0.08) |
| 44.14M | 48.47M | 67.51M | 72.53M | 78.55M | |
| 44.14M | 48.47M | 82.42M | 81.06M | 78.55M |
PLX Earnings Waterfall · TTM
AMEX:PLX · Revenue to Net Income
Key Ratios
Analysis
$76.4M of revenue converted into $15.3M of net income for the selected period. Gross margin is 63.3% and net margin is 2.0%, showing how much revenue survives after costs and taxes. EPS is $0.18, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13G | SC 13G filing | Oct 15, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 9, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 4, 2026 |
How much revenue does PLX generate?
Protalix BioTherapeutics, Inc. (PLX) reported $52.74M of revenue in fiscal 2025.
Is PLX profitable?
Protalix BioTherapeutics, Inc. (PLX) reported -$6.60M of net income, with a net margin of -12.5%.
Continue the stock analysis
Jump to another research area for this company.